A metabolic disease resulting in elevated blood glucose levels, type-2 diabetes affects approximately 462 million people globally. Although its prevalence appears to be increasing, type-2 diabetes has been associated with various potentially preventable risk factors, including infectious diseases. The protozoal infection with Toxoplasma gondii (Nicolle et Manceaux, 1908) has been associated with type-2 diabetes in two previous meta-analyses. Since the publication of the last meta-analysis supporting an association between type-2 diabetes and T. gondii, several new primary studies have investigated this association. In this meta-analysis, we sought to further characterise the association between type-2 diabetes and T. gondii. We identified primary studies using PubMed, Embase, Scopus and Web of Science. Twenty-five studies met our inclusion criteria for a total of 4,639 patients with type-2 diabetes and 3,492 controls. Eighteen primary studies found a positive association between type-2 diabetes and T. gondii, whereas seven did not. Using a frequentist random-effects meta-analysis model, we found an overall summary odds ratio of 2.77 (95-percent confidence interval: 2.03-3.76), suggesting that the odds people will have type-2 diabetes is 2.7 times higher for people seropositive for T. gondii. Future studies should investigate this association in additional geographical regions and explore whether this association is due to the immunosuppressive effects of type-2 diabetes or whether T. gondii directly or indirectly affects glucose metabolism, or both.

The Department of Biophysics Brigham Young University Provo Utah

The Department of Data Analytics and Information Systems Utah State University Logan Utah

The Department of Psychology Brigham Young University Provo Utah

The Neuroscience Center Brigham Young University Provo Utah

See more in PubMed

Ahmed A.K., Kamal A.M., Abdel Fatah M.M., Abd Rabou R.A.M., Mahmoud H.A.H., Sanadeki M.M. 2023: Seroepidemiology of Toxoplasma gondii infection in diabetic patients and the impact of toxoplasmosis on diabetes associated complications in Minia City, Egypt. Infect. Dis. Trop. Med. 9: e1198.

Ahuja S.K., Ahuja S.S., Thelmo W., Seymour A., Phelps K.R. 1993: Necrotizing pancreatitis and multisystem organ failure associated with toxoplasmosis in a patient with AIDS. Clin. Infect. Dis. 16: 432-434. PubMed DOI

Alvarado-Esquivel C., Loera-Moncivais N., Hernandez-Tinoco J., Sanchez-Anguiano L.F., Hernandez-Madrid G., Rabago-Sanchez E., Centeno-Tinoco M.M., Sandoval-Carrillo A.A., Salas-Pacheco J.M., Campos-Moreno O.V., Antuna-Salcido E.I. 2017: Lack of association between Toxoplasma gondii infection and diabetes mellitus: a matched case-control study in a Mexican population. J. Clin. Med. Res. 9: 508-511. PubMed DOI

Ashraf T., Sarker P.K., Hosen M.I., Rahman A., Hasan A., Rahman T. 2023: Association of chronic Toxoplasma gondii infection with pro-inflammatory cytokine interleukin (IL)-12 responses in type-2 diabetes mellitus patients of Bangladesh. J. Parasitol. Res. 2023: 3885160. PubMed DOI

Begg C.B., Mazumdar M. 1994: Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. DOI

Berbudi A., Rahmadika N., Tjahjadi A.I., Ruslami R. 2020: Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16: 442-449. PubMed DOI

Casqueiro J., Casqueiro J., Alves C. 2012: Infections in patients with diabetes mellitus: a review of pathogenesis. Ind. J. Endocrinol. Metab. 16 (Suppl 1): S27-36. PubMed DOI

Chávez-Reyes J., Escárcega-González C.E., Chavira-Suárez E., León-Buitimea A., Vázquez-León P., Morones-Ramírez J.R., Villalón C.M., Quintanar-Stephano A., Marichal-Cancino B.A. 2021: Susceptibility for some infectious diseases in patients with diabetes: the key role of glycemia. Front. Publ. Health 9: 559595. PubMed DOI

Chen L., Chen R., Wang H., Liang F. 2015: Mechanisms linking inflammation to insulin resistance. Int. J. Endocrinol. 2015: 508409. PubMed DOI

Dabirzadeh M., Sargazi M., Bagheri S. 2024: Seroepidemiology of Toxoplasma gondii in diabetic patients type 2 by enzyme-linked immunosorbent assay method in Zabol City, 2017-2018. J. Res. Med. Sci. 29: 19. PubMed DOI

Elkholy A.A., Omar R.E., Elbadawy A.M., Elawady M.A., Abou-Ouf E. 2022: Investigating the potential link between seroprevalence of Toxoplasma IgG and both types of diabetes mellitus in Benha City, Egypt. Parasitol. United J. 15: 195-201. DOI

Galaviz K.I., Narayan K.M.V., Lobelo F., Weber M.B. 2018: Lifestyle and the prevention of type 2 diabetes: a status report. Am. J. Lifestyle Med. 12: 4-20. PubMed DOI

Galicia-Garcia U., Benito-Vicente A., Jebari S., Larrea-Sebal A., Siddiqi H., Uribe K.B., Ostolaza H., Martín C. 2020: Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci. 21: 6275. PubMed DOI

Gokce C., Yazar S., Bayram F., Gundogan K., Yaman O., Sahin I. 2008: Anti-Toxoplasma gondii antibodies in type 2 diabetes. Natl. Med. J. India 21: 51.

Hartung J., Knapp G. 2001a: On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat. Med. 20: 1771-1782. PubMed DOI

Hartung J., Knapp G. 2001b: A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat. Med. 20: 3875-3889. PubMed DOI

Hemida M.H., Shahat S.A.R., Bayoumy A.M.S., Mohammad K.A.H. 2017: Prevalence of toxoplasmosis among diabetic patients. Eur. J. Pharm. Med. Res. 4: 137-140.

Inceboz M., Inceboz T. 2021: Toxoplasmosis and neuropsychological effects. Turkiye Parazitol. Derg. 45: 49-55. PubMed DOI

Ioannidis J.P., Trikalinos T.A. 2007: The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Can. Med. Assoc. J. 176: 1091-1096. PubMed DOI

Jalil M.B., Mohammed Ali M.N., Jihad I.A., Alabadi H.I. 2023: Seropositivity of anti-Toxoplasma gondii IgG among type 2 diabetes mellitus patients. Rom. J. Infect. Dis. 26: 111-115. DOI

Kalogeropoulos D., Sakkas H., Mohammed B., Vartholomatos G., Malamos K., Sreekantam S., Kanavaros P., Kalogeropoulos C. 2022: Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int. Ophthalmol. 42: 295-321. PubMed DOI

Khalili M., Mahami-Oskouei M., Shahbazi A., Safaiyan A., Mohammadzadeh-Gheshlaghi N., Mahami-Oskouei L. 2018: The correlation between serum levels of anti-Toxoplasma gondii antibodies and the risk of diabetes. Iran J. Parasitol. 13: 637-642.

Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. 2020: Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J. Epidemiol. Glob. Health. 10: 107-111. PubMed DOI

Kiselar J.G., Wang X., Dubyak G.R., El Sanadi C., Ghosh S.K., Lundberg K., Williams W.M. 2015: Modification of beta-defensin-2 by dicarbonyls methylglyoxal and glyoxal inhibits antibacterial and chemotactic function in vitro. PLoS One 10: e0130533. PubMed DOI

Li Y.X., Xin H., Zhang X.Y., Wei C.Y., Duan Y.H., Wang H.F., Niu H.T. 2018: Toxoplasma gondii infection in diabetes mellitus patients in China: seroprevalence, risk factors, and case-control studies. Biomed. Res. Int. 2018: 4723739. PubMed DOI

Majidiani H., Dalvand S., Daryani A., Galvan-Ramirez M.L., Foroutan-Rad M. 2016: Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Braz. J. Infect. Dis. 20: 605-609. PubMed DOI

Mariuz P., Bosler E.M., Luft B.J. 1997: Toxoplasma pneumonia. Semin. Respir. Infect. 12: 40-43.

Mohamed G.A., Ez Eldeen M.E., Elossily N.A., Gaber M., Hassan T.M., Mahran Z.G., Hetta H.F., Abdel Aziz E.M. 2020: Anti-Toxoplasma IgG level in type 2 diabetic patients: does it affect glycemic control? Egypt. J. Immunol. 27: 119-127.

Mohammed K. 2025: The possible association between chronic toxoplasmosis and type-2 diabetes mellitus in women: a case-control study. Cureus 17: e79120. PubMed DOI

Mohammed T., Yaseen A.N., Aldabagh A.H. 2020: Evaluation of soluble PD-1 and PD-L1 Iraqi type 2 diabetes mellitus (T2DM) patients with chronic toxoplasmosis. Medico-Legal Update 20: 477-481.

Molan A.L., Ismail M.H. 2021: Is there a positive association between Toxoplasma gondii seropositivity and obesity in diabetic patients? Ann. Parasitol. 67: 537-542.

Molan A., Nosaka K., Hunter M., Wang W. 2020: The association between Toxoplasma gondii and type 2 diabetes mellitus: a systematic review and meta-analysis of human case-control studies. Bull. Natl. Res. Centre 44: 1-8. DOI

Montoya J.G., Liesenfeld O. 2004: Toxoplasmosis. Lancet 363: 1965-1976. PubMed DOI

Nassief Beshay E.V., El-Refai S.A., Helwa M.A., Atia A.F., Dawous M.M. 2018: Toxoplasma gondii as a possible causative pathogen of type-1 diabetes mellitus: evidence from case-control and experimental studies. Exp. Parasitol. 188: 93-101. PubMed DOI

Oz H.S. 2014: Toxoplasmosis, pancreatitis, obesity and drug discovery. Pancreat. Disord. Ther. 4: 138.

Özçelik S., Alim M., Ozpinar N. 2020: Detection of Toxoplasma gondii infection among diabetic patients in Turkey. Clin. Epidemiol. Glob. Health 8: 899-902. DOI

Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hrobjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., McGuinness L.A., Stewart L.A., Thomas J., Tricco A.C., Welch V.A., Whiting P., Moher D. 2021: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J. Clin. Epidemiol. 134: 178-189. PubMed DOI

Park E.A., Han I.H., Kim J.H., Park S.J., Ryu J.S., Ahn M.H. 2019: Production of inflammatory cytokines and nitric oxide by human mast cells incubated with Toxoplasma gondii lysate. Kor. J. Parasitol. 57: 201-206. PubMed DOI

Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. 2006: Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. PubMed DOI

Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. 2008: Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J. Clin. Epidemiol. 61: 991-996. PubMed DOI

Pradeepa R., Mohan V. 2017: Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur. J. Clin. Nutr. 71: 816-824. PubMed DOI

Prandota J. 2013: T gondii infection acquired during pregnancy and/or after birth may be responsible for the development of both type 1 and 2 diabetes mellitus. J. Diabetes Metabol. 4: 1000241. DOI

Qudus J., Haider K. 2019: The relation of Toxoplasma gondii with tumor-necrotizing factor-α in type II diabetic patients. Res. J. Pharm. Technol. 12: 4817-4821. DOI

R Core Team (Ed.) 2024: A Language and Environment for Statistical Computing. https://www.r-project.org/2025.

Saeed S.A., Al-Aubaidi I.K. 2024: Prevalence of toxoplasmosis in Iraqi patients with diabetic type 2. Roman. J. Infect. Dis. 27: 144-150. DOI

Saheb E. 2017: Detection of toxoplasmosis infection in diabetic patients. Diyala J. Med. 12: 70-74.

Saki J., Khodkar I., Shandnoosh F., Safi M., Ghadiri A., Shaefieenia S. 2022: Study of toxoplasmosis in type 2 diabetic patients using ELISA and B1 nested-PCR methods. Ann. Parasitol. 68: 367-373.

Salem D.A., Salem N.A., Hendawy S.R. 2021: Association between Toxoplasma gondii infection and metabolic syndrome in obese adolescents: a possible immune-metabolic link. Parasitol. Int. 83: 102343. PubMed DOI

Salman O.D., Merdaw M.A.Z., Almaliky A.A. 2023: The probable association between Type 2 diabetes mellitus and Toxoplasma gondii infection. Int. J. Drug Del. Tech. 13: 131-135. DOI

Shamsinia S., Dalimi A., Pirestani M. 2019: Is toxoplasmosis a risk factor in diabetic patients in Tehran? Infect. Epidemiol. Microbiol. 5: 49-59.

Sidik K., Jonkman J.N. 2002: A simple confidence interval for meta-analysis. Stat. Med. 21: 3153-3159. PubMed DOI

Smith N.C., Goulart C., Hayward J.A., Kupz A., Miller C.M., van Dooren G.G. 2021: Control of human toxoplasmosis. Int. J. Parasitol. 51: 95-121. PubMed DOI

Soltani S., Tavakoli S., Sabaghan M., Kahvaz M.S., Pashmforosh M., Foroutan M. 2021: The probable association between chronic Toxoplasma gondii infection and type 1 and type 2 diabetes mellitus: a case-control study. Interdiscipl. Perspect. Infect. Dis. 2021: 2508780. PubMed DOI

Viechtbauer W. 2010: Conducting meta-analyses in R with the metafor package. J. Statist. Software 36: 1-48. DOI

Wells G. 2001: The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Xiao J., Savonenko A., Yolken R.H. 2022: Strain-specific pre-existing immunity: a key to understanding the role of chronic Toxoplasma infection in cognition and Alzheimer's diseases? Neurosci. Biobehav. Rev. 137: 104660. PubMed DOI

Younis E.Z., Elamami A.H. 2018: Anti-Toxoplasma gondii IgG, IgM, and IgA among type-2 diabetic patients in Benghazi Libya: a comparison study. J. Immunol. Microbiol. 2: 2.